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Chromosome 9 open reading frame 72 (C9orf72) is a 
protein with unknown function and a high level of 
expression in the brain and spinal cord. Th e discovery of 
expanded heptanucleotide repeat mutations as the most 
common genetic cause of familial and sporadic fronto-
temporal dementia (FTD) and amyotrophic lateral 
sclerosis (ALS) [1,2] provided further evidence for a 
phenotypic spectrum with overlapping genetic [3-5], 
pathological [6,7], and clinical [8,9] features. C9orf72
mutant FTD and ALS (C9FTD/ALS) cases reveal a 
characteristic neuro pathological signature with abundant 
p62-positive inclusions in the hippocampus and cere-
bellum [6,7] and a unique pattern of ubiquilin pathology 
[10]. C9orf72 repeat expansion mutation in large cohorts 
of patients with AD has been either absent [11] or 
identiﬁ ed exceed ingly rarely [12].
In the previous issue of Alzheimer’s Research & Th erapy, 
Satoh and colleagues [13] present an analysis of C9orf72 
expression and its relation to ubiquitin, p62, and 
ubiquilin-1, ubiquilin-2 immuno reactivity in control, 
Alzheimer’s disease (AD), sporadic ALS, Parkinson’s 
disease, and multiple system atrophy brains. Early studies 
have consistently shown that C9orf72 is negative in 
intracellular inclusions including tau-positive structures 
except for Pick bodies (for references, see [13]). In 
contrast to these previous studies, Satoh and colleagues 
report C9orf72 in a subset of dystrophic neurites in AD. 
Another major ﬁ nding is the demonstration of C9orf72 
and ubiquilin-1 positivity in a cluster of dystrophic 
neurites in senile plaques in AD brains by using 
antibodies discriminating ubiquilin-1 from ubiquilin-2; 
these results warrant further studies into the role of 
ubiquilin in neurodegeneration. Th e thorough analysis of 
two diﬀ er ent anti-C9orf72 antibodies for the pattern of 
immuno reactivity, speciﬁ city, cross-reactivities is an 
important aspect of the study. Th e results suggest that 
the testing of further antibodies available on the market 
and the genera tion of novel highly speciﬁ c anti-C9orf72 
anti bodies are necessary to facilitate research into neuro-
degenerative diseases, in particular C9FTD/ALS. Unfor-
tu nately, C9orf72 mutation status has not been analyzed 
in the included cases either; Satoh and colleagues assume 
that cases are likely to be negative in view of the low 
prevalence of C9orf72 mutation in ALS and FTD in 
Japanese patients [14] in comparison with Caucasian 
patients [15]. Pathological proteins incorporated into 
charac teristic inclu sions in neurodegenerative diseases 
are rather detergent-insoluble; the analysis of this key 
feature is still awaited. Th e case numbers are low in this 
study. Th erefore, as the authors themselves have suggested, 
further studies are needed to test the presented ﬁ ndings in 
larger cohorts and by more detailed analysis. Th is paper 
provides a nidus around which the presented observations 
can be more robustly studied and clariﬁ ed.
Abbreviations
AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; C9FTD/ALS, 
frontotemporal dementia or amyotrophic lateral sclerosis (or both) linked 
to chromosome 9; C9orf72, chromosome 9 open reading frame 72; FTD, 
frontotemporal dementia.
Competing interests
The author declares that he has no competing interests.
Abstract
Mutation in chromosome 9 open reading frame 72 
(C9orf72) is a major genetic cause of frontotemporal 
dementia (FTD) and amyotrophic lateral sclerosis 
(ALS), referred to as C9FTD/ALS. The function 
of the protein is currently unknown, and the 
pathomechanism of C9FTD/ALS remains to be 
elucidated. The study by Satoh and colleagues in 
the previous issue of Alzheimer’s Research & Therapy 
presents important new fi ndings on C9orf72 protein 
expression in neurodegenerative disorders along with 
characterization of C9orf72 antibodies.
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